To validate that KDM6A alterations occurred at an increased frequency within RT-associated bladder cancer, we calculated the proportion of KDM6A altered tumors in the DFCI validation cohort and in a non-RT cohort, TCGA bladder study (17). The gene discussed is KDM6A; the disease is urinary bladder carcinoma.